1994PubMedRequires access

Characteristics of Ki1769, a novel vasodilator, in isolated rat aorta.

Tomoko Kashiwabara, Terumi Nakajima, Haruo Kasai, Satoru Nakajima, Tetsuya Izawa, N. Ogawa

Open publisher page 1 citations

Abstract

The vasorelaxant mechanism of a newly synthesized vasodilator, Ki1769 [N-cyano-N'-(2-phenethyl)-3-pyridinecarboximidamide], was studied in isolated rat aorta in comparison with cromakalim. Ki1769 (10(-8)-10(-5) M) and cromakalim (10(-8)-10(-5) M) produced a concentration-dependent relaxation and the EC50 values for Ki1769 and cromakalim were (8.60 +/- 1.90) x 10(-7) M and (1.36 +/- 0.18) x 10(-7) M, respectively. Ki1769- and cromakalim-induced relaxations were competitively antagonized by glibenclamide with pA2 values of 6.83 and 6.93, respectively. Charybdotoxin, apamine, atropine, propranolol and indomethacin did not affect the Ki1769-induced relaxation. An increase in 86Rb efflux was induced by Ki1769. Glibenclamide attenuated the increase in 86Rb efflux produced by Ki1769. These results suggest that the vasorelaxant effect of Ki1769 is based on the glibenclamide-sensitive K channel-opening action.

About this research paper

What this paper is about

The vasorelaxant mechanism of a newly synthesized vasodilator, Ki1769 [N-cyano-N'-(2-phenethyl)-3-pyridinecarboximidamide], was studied in isolated rat aorta in comparison with cromakalim. Ki1769 (10(-8)-10(-5) M) and cromakalim (10(-8)-10(-5) M) produced a concentration-dependent relaxation and the EC50 values for Ki1769 and cromakalim were (8.60 +/- 1.90) x 10(-7) M and (1.36 +/- 0.18) x 10(-7) M, respectively. Ki1769- and cromakalim-induced relaxations were competitively antagonized by glibenclamide with pA2 values of 6.83 and 6.93, respectively. Charybdotoxin, apamine, atropine, propranolol and indomethacin did not affect the Ki1769-induced relaxation. An increase in 86Rb efflux was induced by Ki1769. Glibenclamide attenuated the increase in 86Rb efflux produced by Ki1769. These results suggest that the vasorelaxant effect of Ki1769 is based on the glibenclamide-sensitive K channel-opening action.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The vasorelaxant mechanism of a newly synthesized vasodilator, Ki1769 [N-cyano-N'-(2-phenethyl)-3-pyridinecarboximidamide], was studied in isolated rat aorta in comparison with cromakalim. Ki1769 (10(-8)-10(-5) M) and cromakalim (10(-8)-10(-5) M) produced a concentration-dependent relaxation and the EC50 values for Ki1769 and cromakalim were (8.60 +/- 1.90) x 10(-7) M and (1.36 +/- 0.18) x 10(-7) M, respectively. Ki1769- and cromakalim-induced relaxations were competitively antagonized by glibenclamide with pA2 values of 6.83 and 6.93, respectively. Charybdotoxin, apamine, atropine, propranolol and indomethacin did not affect the Ki1769-induced relaxation. An increase in 86Rb efflux was induced by Ki1769. Glibenclamide attenuated the increase in 86Rb efflux produced by Ki1769. These results suggest that the vasorelaxant effect of Ki1769 is based on the glibenclamide-sensitive K channel-opening action.

Key concepts: Cromakalim, Glibenclamide, Charybdotoxin, Vasodilation, Chemistry, Apamin, Potassium channel, Propranolol

Related papers

Back to paper searchBrowse research topicsOriginal source
Characteristics of Ki1769, a novel vasodilator, in isolated rat aorta. — Research Paper | ScholarLens